TW201922282A - Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 - Google Patents

Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 Download PDF

Info

Publication number
TW201922282A
TW201922282A TW107136004A TW107136004A TW201922282A TW 201922282 A TW201922282 A TW 201922282A TW 107136004 A TW107136004 A TW 107136004A TW 107136004 A TW107136004 A TW 107136004A TW 201922282 A TW201922282 A TW 201922282A
Authority
TW
Taiwan
Prior art keywords
antibody
tumors
use according
tumor
cancer
Prior art date
Application number
TW107136004A
Other languages
English (en)
Chinese (zh)
Inventor
韓為東
王春萌
劉洋
楊清明
聶晶
沈連軍
陶維康
鄒建軍
曹國慶
楊昌永
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
中國人民解放軍總醫院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 中國人民解放軍總醫院 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW201922282A publication Critical patent/TW201922282A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107136004A 2017-10-13 2018-10-12 Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 TW201922282A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710949761 2017-10-13
??201710949761.5 2017-10-13

Publications (1)

Publication Number Publication Date
TW201922282A true TW201922282A (zh) 2019-06-16

Family

ID=66100431

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107136004A TW201922282A (zh) 2017-10-13 2018-10-12 Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途

Country Status (3)

Country Link
CN (1) CN111132696B (fr)
TW (1) TW201922282A (fr)
WO (1) WO2019072220A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511293A (ja) * 2018-01-12 2021-05-06 ビラクタ セラピューティクス，インク． 細胞免疫療法で使用されるエピジェネティック修飾因子
WO2021057764A1 (fr) * 2019-09-24 2021-04-01 江苏恒瑞医药股份有限公司 Utilisation d'un anticorps pd-1 en combinaison avec un composé taxoïde dans la préparation de médicaments pour le traitement du cancer du sein triple-négatif
GB201913988D0 (en) * 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
CN113116879A (zh) * 2020-01-15 2021-07-16 江苏恒瑞医药股份有限公司 法米替尼联合紫杉类和铂类药物在制备治疗肿瘤疾病的药物中的用途
CN113413389B (zh) * 2021-07-19 2024-03-15 成都赜灵生物医药科技有限公司 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途
CN116196415B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 用于增敏pd-1抗体的混合制剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035112A1 (fr) * 2013-09-05 2015-03-12 The Johns Hopkins University Thérapie anticancéreuse par l'intermédiaire d'une combinaison de modulation épigénétique et modulation immunitaire
EA035037B1 (ru) * 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
WO2016010879A1 (fr) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression de cellules suppressives d'origine myéloïde et blocage de point de contrôle immunitaire
SI3182996T1 (sl) * 2014-08-22 2023-04-28 Celgene Corporation Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
AU2016329960A1 (en) * 2015-09-28 2018-04-26 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine

Also Published As

Publication number Publication date
CN111132696B (zh) 2023-05-16
CN111132696A (zh) 2020-05-08
WO2019072220A1 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN111936164B (zh) 癌的治疗和/或预防用药物组合物
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
JP7506981B2 (ja) Ｔｌｒ７アゴニストを含む併用薬
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
JP2012500180A5 (fr)
WO2021182573A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
JP2018516968A (ja) 医薬組み合わせおよびその使用
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
CN108079292A (zh) 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
KR20200078483A (ko) 간암 치료를 위한 조성물 및 방법
EP4069300A1 (fr) Méthodes pour renforcer l'immunité et pour le traitement de tumeur
WO2023174408A1 (fr) Combinaison pharmaceutique d'anticorps anti-tim-3 et d'anticorps anti-pd-l1
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
WO2021182571A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
JP2021508699A (ja) トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用
WO2023174278A1 (fr) Composition pharmaceutique d'anticorps anti-tim-3 et d'agent d'hypométhylation
CN117224689B (zh) 联合抗her2抗体和化疗剂治疗胃癌的用途
RU2774721C2 (ru) Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы
CN118871129A (zh) 抗tim-3抗体与去甲基化药物的药物组合